Clinical trials: Urinary Tract Cancer
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Urinary Bladder Neoplasms, Colorectal Cancer
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.
- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT05397171
- Testing
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Where
- 6 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Cancer, Solid Tumor
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay.
- Conditions
- Cancer, Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- MARIA (NCT05219734)
- Testing
- Personalized Cancer Monitoring (PCM)
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- Invitae Corporation
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Phase Ib: Explore the safety and tolerability of BL-M07D1 to further define RP2D in a variety of solid tumors, including locally advanced or metastatic urinary and gastrointestinal tumors.
- Trial name
- NCT06031584
- Testing
- BL-M07D1
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Ovarian Cancer, Bladder Cancer
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as…
- Conditions
- Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04580485
- Testing
- INCB106385, INCMGA00012
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Urothelial Carcinoma
Registry Platform Urologic Cancer
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- CARAT (NCT03374267)
- Testing
- Routine care as per site standard.
- Where
- Germany
- Volunteers
- 2,230 people
- Sponsor
- iOMEDICO AG
Bladder Cancer, Gastric Cancer
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies.
- Conditions
- Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT04383938
- Testing
- APR-246 (eprenetapopt) + Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aprea Therapeutics
Solid Tumors
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT04774952
- Testing
- RMC-5552
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Revolution Medicines, Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Prostate Cancer
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
The purpose of this trial was to see how well a new trial drug (degarelix) worked on lower urinary tract symptoms (also known as LUTS) in prostate cancer patients as compared to how a standard drug hormonal treatment worked on…
- Trial name
- NCT00831233
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 33 sites in Germany, Spain and 1 more
- Volunteers
- 42 people
- Sponsor
- Ferring Pharmaceuticals
Locally Advanced Solid Tumor, Metastatic Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer
- Trial name
- NCT04319757
- Testing
- ACE1702, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- Acepodia Biotech, Inc.
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Urinary Tract Cancer
A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer
This study will evaluate the efficacy and safety of a chemotherapy regimen of intravenous Herceptin, cisplatin and gemcitabine in patients with metastatic urothelial cancer.
- Trial name
- NCT02006667
- Testing
- trastuzumab, gemcitabine, cisplatin
- Where
- 7 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH
Breast Cancer, Non Small Cell Lung Cancer
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. Participants participated in a dose-escalation phase (Part 1) and were due to participate in the dose expansion phase (Part 2).
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
- Trial name
- NCT03125200
- Testing
- ADCT-502
- Where
- 5 sites in United States, Belgium
- Volunteers
- 21 people
- Sponsor
- ADC Therapeutics S.A.
Tumor
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
- Trial name
- CheckMate 76U (NCT04311710)
- Testing
- ipilimumab, nivolumab, ENHANZE (rHuPH20)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb